Which incretin-based therapy for type 2 diabetes?
Texte intégral
Figure
Documents relatifs
Enseignements pour la pratique clinique - Confirmation de l’efficacité de l’alfuzosine sur le long terme dans le contexte d’une pathologie exposant à de nombreuses années
The major advantages of this study in which we developed a population pharmacokinetic model for both formulations in comparison to a model developed for
Type 2 Diabetes Mellitus (T2DM) leads to bone fragility and predisposes to increased risk of 19.. fracture, poor bone healing and other
The aim of the present meta-analysis was to assess whether patients with T2DM treated with GLP-1 receptor agonists (GLP-1Ra) present a lower incidence of
In add- ition, there is consistent evidence based on clinical data that adherence in once-daily (QD) regimen is superior to twice-daily (BID) appli- cation, in particular with regard
The aim of our study was therefore to investigate the relationship between remission status and meal- stimulated proinsulin, C-peptide, GLP-1, and glucagon plasma concentrations in
Type 2 Diabetes Mellitus (T2DM) leads to bone fragility and predisposes to increased risk of 19.. fracture, poor bone healing and other
The aim of the present meta-analysis was to assess whether patients with T2DM treated with GLP-1 receptor agonists (GLP-1Ra) present a lower incidence of